Arun Singh

发表

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis

M. Mathews, S. Gopal, I. Nuamah, 2021, Patient preference and adherence.

Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

M. Mathews, S. Gopal, I. Nuamah, 2020, Patient preference and adherence.

NDT_A_221242 1533..1542

M. Mathews, S. Gopal, A. Savitz, 2020 .

Hip Fracture Risk After Treatment with Tramadol or Codeine: An Observational Study

M. Schuemie, E. Voss, D. Fife, 2022, Drug Safety.

PPA_A_322880 2239..2248

M. Mathews, S. Gopal, I. Nuamah, 2021 .

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia

S. Galderisi, S. Gopal, P. Lim, 2021, The international journal of neuropsychopharmacology.

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

M. Mathews, S. Gopal, A. Savitz, 2020, Neuropsychiatric disease and treatment.

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.

M. Pompili, S. Gopal, M. García-Portilla, 2023, Neuropsychiatric disease and treatment.

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

M. Mathews, S. Gopal, Edward Kim, 2020, Neuropsychiatric disease and treatment.